The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S. Zepbound, whose scientific name is tirzepatide ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the ...

In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks highlighted in Jim Cramer’s latest calls. Jim Cramer in a recent program talked ...

Dec 11 (Reuters) - Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's (LLY.N), opens new tab weight-loss drug Zepbound to patients with obesity, becoming the ...

Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound. The company also raised its ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a welcome predicament: What to do with all that cash? One answer ...